Key Points

  • Mass spectrometry–based proteomics is a powerful technique that can identify IGVL gene products from tissue specimens.

  • High frequency of IGKV1-8 usage in cystic lung LCDD partially explains pulmonary tropism and argues for a distinct entity.

Abstract

We previously reported a new form of light chain deposition disease (LCDD) presenting as diffuse cystic lung disorder that differs from the usual systemic form with respect to patient age, the male/female ratio, the involved organs, and the hematologic characteristics. We also demonstrated that the light chains were produced by an intrapulmonary B-cell clone and that this clone shared a stereotyped antigen receptor IGHV4-34/IGKV1. However, we only analyzed 3 patients. We conducted a retrospective study including lung tissue samples from 24 patients with pulmonary LCDD (pLCDD) matched with samples from 13 patients with pulmonary κ light chain amyloidosis (pAL amyloidosis) used as controls. Mass spectrometry–based proteomics identified immunoglobulin κ peptides as the main protein component of the tissue deposits in all patients. Interestingly, in pLCDD, IGKV1 was the most common κ family detected (86.4%), and IGKV1-8 was overrepresented compared with pAL amyloidosis (75% vs 11.1%, P = .0033). Furthermore, IGKV1-8 was predominantly associated with a diffuse cystic pattern (94%) in pLCDD. In conclusion, the high frequency of IGKV1-8 usage in cystic pLCDD constitutes an additional feature arguing for a specific entity distinct from the systemic form that preferentially uses IGKV4-1.

REFERENCES

REFERENCES
1.
Buxbaum
JN
,
Chuba
JV
,
Hellman
GC
,
Solomon
A
,
Gallo
GR
.
Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis
.
Ann Intern Med
.
1990
;
112
(
6
):
455
-
464
.
2.
Colombat
M
,
Stern
M
,
Groussard
O
, et al
.
Pulmonary cystic disorder related to light chain deposition disease
.
Am J Respir Crit Care Med
.
2006
;
173
(
7
):
777
-
780
.
3.
Hirschi
S
,
Colombat
M
,
Kessler
R
, et al
.
Lung transplantation for advanced cystic lung disease due to nonamyloid kappa light chain deposits
.
Ann Am Thorac Soc
.
2014
;
11
(
7
):
1025
-
1031
.
4.
Nasr
SH
,
Valeri
AM
,
Cornell
LD
, et al
.
Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution
.
Clin J Am Soc Nephrol
.
2012
;
7
(
2
):
231
-
239
.
5.
Joly
F
,
Cohen
C
,
Javaugue
V
, et al
.
Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study
.
Blood
.
2019
;
133
(
6
):
576
-
587
.
6.
Colombat
M
,
Mal
H
,
Copie-Bergman
C
, et al
.
Primary cystic lung light chain deposition disease: a clinicopathologic entity derived from unmutated B cells with a stereotyped IGHV4-34/IGKV1 receptor
.
Blood
.
2008
;
112
(
5
):
2004
-
2012
.
7.
Vrana
JA
,
Gamez
JD
,
Madden
BJ
,
Theis
JD
,
Bergen
HR
III
,
Dogan
A
.
Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens
.
Blood
.
2009
;
114
(
24
):
4957
-
4959
.
8.
Vrana
JA
,
Theis
JD
,
Dasari
S
, et al
.
Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics
.
Haematologica
.
2014
;
99
(
7
):
1239
-
1247
.
9.
Colombat
M
,
Holifanjaniaina
S
,
Guillonneau
F
, et al
.
Mass spectrometry-based proteomic analysis: a good diagnostic tool for cystic lung light chain deposition disease
.
Am J Respir Crit Care Med
.
2013
;
188
(
3
):
404
-
405
.
10.
Dasari
S
,
Theis
JD
,
Vrana
JA
, et al
.
Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies
.
J Proteome Res
.
2015
;
14
(
4
):
1957
-
1967
.
11.
Kourelis
TV
,
Dasari
S
,
Theis
JD
, et al
.
Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry
.
Blood
.
2017
;
129
(
3
):
299
-
306
.
12.
Denoroy
L
,
Déret
S
,
Aucouturier
P
.
Overrepresentation of the V kappa IV subgroup in light chain deposition disease
.
Immunol Lett
.
1994
;
42
(
1-2
):
63
-
66
.
13.
Khamlichi
AA
,
Rocca
A
,
Touchard
G
,
Aucouturier
P
,
Preud’homme
JL
,
Cogné
M
.
Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model
.
Blood
.
1995
;
86
(
10
):
3655
-
3659
.
14.
Comenzo
RL
,
Zhang
Y
,
Martinez
C
,
Osman
K
,
Herrera
GA
.
The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden
.
Blood
.
2001
;
98
(
3
):
714
-
720
.
15.
Perfetti
V
,
Casarini
S
,
Palladini
G
, et al
.
Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment
.
Blood
.
2002
;
100
(
3
):
948
-
953
.
16.
Abraham
RS
,
Geyer
SM
,
Price-Troska
TL
, et al
.
Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL)
.
Blood
.
2003
;
101
(
10
):
3801
-
3808
.
17.
Perfetti
V
,
Palladini
G
,
Casarini
S
, et al
.
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44
.
Blood
.
2012
;
119
(
1
):
144
-
150
.
You do not currently have access to this content.